Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - frusemide -

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - frusemide -

Australia - English - Department of Health (Therapeutic Goods Administration)

scentia pharmaceuticals pty ltd - frusemide -

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - furosemide, quantity: 20 mg - tablet - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate type a; maize starch; magnesium stearate - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - furosemide, quantity: 40 mg - tablet - excipient ingredients: lactose monohydrate; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; maize starch - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - furosemide, quantity: 250 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - frusemide sandoz injection high dose (250 mg/25 ml). frusemide high dose formulation (250 mg/25 ml) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure (e.g. in the post-operative phase and in association with septic infections), in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function (e.g. in chronic glomerular nephritis, lupus erythematous and kimmelstiel-wilson syndrome). if diuresis is less than 2.5 l/day, dialysis has to be used.

Kenya - English - Pharmacy and Poisons Board

gracure pharmaceuticals ltd e-1105 riico lndustrialarea phase-lll bhiwadi - frusemide - tablet - frusemide 40mg - high-ceiling diuretics: plain sulfonamides

Kenya - English - Pharmacy and Poisons Board

biodeal laboratories ltd p.o. box 32040 nairoki kenya - frusemide - tablet - frusemide 40mg - high-ceiling diuretics: plain sulfonamides

Kenya - English - Pharmacy and Poisons Board

questa care inc. c/o surgilinks ltd questa care inc. 4251 s. higuera st. suite 800 - frusemide bp - injection - frusemide bp 10mg/2ml - high-ceiling diuretics: plain sulfonamides